Dyadic International Upgraded By OTC Markets To "Current Information" Tier

  Dyadic International Upgraded By OTC Markets To "Current Information" Tier

Highest trading tier on the OTC Pink marketplace

PR Newswire

JUPITER, Fla., Jan. 23, 2013

JUPITER, Fla., Jan. 23, 2013 /PRNewswire/ -- Dyadic International, Inc., a
global biotechnology company focused on the discovery, development,
manufacture and sale of enzymes and other proteins for the bioenergy,
bio-based chemicals, biopharmaceuticals and industrial enzyme industries,
announced today that it has been upgraded by OTC Markets to "Current
Information" which is the highest trading tier on the OTC Pink marketplace.
The disclosures required for this upgrade have been posted on the OTC Markets
website (www.otcmarkets.com) under Dyadic's ticker symbol, "DYAI."

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and CEO, Mark Emalfarb, stated, "Completion of the upgrade
to OTC Pink Current Information is one of several positive steps Dyadic has
taken to strengthen our stockholder base and build stockholder value by
providing greater transparency through periodic press releases and quarterly
and annual disclosures, financial statements and investor conference calls.
The confidence and protections provided by these additional disclosures
contribute to the significantly greater liquidity of the OTC Pink Current
Information Tier as compared to the prior tier assigned to Dyadic."

The Current Information Tier applies to reporting companies that submit
filings to regulators with powers of review and that make the filings publicly
available and non-reporting companies that make current information publicly
available on the OTC Disclosure and News Service pursuant to OTC Markets
Guidelines for Providing Adequate Current Information. Disclosures are
published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph
(a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its
patented and proprietary technologies to conduct research, development and
commercial activities for the discovery, development, manufacture and sale of
enzymes and other proteins for the bioenergy, bio-based chemicals,
biopharmaceuticals and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and
proprietary C1 fungus, which enables the development and large scale
manufacture of low cost enzymes and other proteins for diverse market
opportunities. The C1 platform technology can also be used to screen for the
discovery of novel genes and proteins. Dyadic actively pursues licensing
arrangements and other commercial opportunities to leverage the value of these
technologies by providing its partners and collaborators with the benefits of
manufacturing and/or utilizing the enzymes which these technologies help
produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking
statements. These forward-looking statements involve risks and uncertainties
that could cause Dyadic's actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Except as required by
law, Dyadic expressly disclaims any intent or obligation to update any
forward-looking statements.

SOURCE Dyadic International, Inc.

Website: http://www.dyadic.com
Contact: Dyadic International, Inc., Adam J. Morgan, Esq., Vice President
General Counsel & Business Development, +1-561-743-8333, amorgan@dyadic.com
 
Press spacebar to pause and continue. Press esc to stop.